Express Scripts/Medco Health Solutions
On July 21, 2011, Express Scripts, Inc. (Nasdaq: ESRX) and Medco Health Solutions, Inc. (NYSE: MHS) today announced that they have entered into a definitive merger agreement. Under the agreement, Medco shareholders will receive $71.36 per share in cash and stock, or $29.1 billion.
Medco shareholders will receive $28.80 in cash and 0.81 shares for each Medco share they own upon closing of the transaction.
Detail from the release: "Under the terms of the agreement, Express Scripts shall form a new holding company called Express Scripts Holding Company. Medco shareholders will receive $28.80 in cash and 0.81 shares of Express Scripts Holding Company for each Medco share they own upon closing of the transaction, and Express Scripts shareholders will become shareholders of Express Scripts Holding Company receiving one share of the new holding company for each share of Express Scripts that they own upon closing. Based on the closing price of Express Scripts stock of $52.54 as of July 20, 2011, the stock component is valued at $42.56 per share, which, when combined with the $28.80 in cash brings the total value per share to Medco shareholders of $71.36. This represents a premium to Medco shareholders of 28 percent over Medco's closing share price on July 20, 2011. Upon closing of the transaction, Express Scripts shareholders are expected to own approximately 59 percent of the combined company and Medco shareholders are expected to own approximately 41 percent.
The transaction provides certain value to Medco shareholders through the cash component, as well as continued participation in the future prospects expected to result from the combination through their ownership of approximately 41 percent of Express Scripts Holding Company shares.
The merger is subject to regulatory clearance and Express Scripts' and Medco's shareholder approvals and other customary closing conditions. The terms of the merger agreement provide for the payment of termination fees in certain circumstances, but not in connection with the failure to obtain regulatory clearance. The transaction is expected to close in the first half of 2012.
The corporate headquarters will be in St. Louis and George Paz will serve as chairman and CEO of the combined organization. The Board of Directors will be expanded to include two current independent Medco board members."
Express Scripts' financial advisors are Credit Suisse and Citigroup Global Markets, Inc. Its legal advisor is Skadden, Arps, Slate, Meagher & Flom, LLP. Medco's co-lead financial advisors are J.P. Morgan and Lazard, its legal advisor is Sullivan & Cromwell LLP and its regulatory counsel is Dechert LLP.
Medco shareholders will receive $28.80 in cash and 0.81 shares for each Medco share they own upon closing of the transaction.
Detail from the release: "Under the terms of the agreement, Express Scripts shall form a new holding company called Express Scripts Holding Company. Medco shareholders will receive $28.80 in cash and 0.81 shares of Express Scripts Holding Company for each Medco share they own upon closing of the transaction, and Express Scripts shareholders will become shareholders of Express Scripts Holding Company receiving one share of the new holding company for each share of Express Scripts that they own upon closing. Based on the closing price of Express Scripts stock of $52.54 as of July 20, 2011, the stock component is valued at $42.56 per share, which, when combined with the $28.80 in cash brings the total value per share to Medco shareholders of $71.36. This represents a premium to Medco shareholders of 28 percent over Medco's closing share price on July 20, 2011. Upon closing of the transaction, Express Scripts shareholders are expected to own approximately 59 percent of the combined company and Medco shareholders are expected to own approximately 41 percent.
The transaction provides certain value to Medco shareholders through the cash component, as well as continued participation in the future prospects expected to result from the combination through their ownership of approximately 41 percent of Express Scripts Holding Company shares.
The merger is subject to regulatory clearance and Express Scripts' and Medco's shareholder approvals and other customary closing conditions. The terms of the merger agreement provide for the payment of termination fees in certain circumstances, but not in connection with the failure to obtain regulatory clearance. The transaction is expected to close in the first half of 2012.
The corporate headquarters will be in St. Louis and George Paz will serve as chairman and CEO of the combined organization. The Board of Directors will be expanded to include two current independent Medco board members."
Express Scripts' financial advisors are Credit Suisse and Citigroup Global Markets, Inc. Its legal advisor is Skadden, Arps, Slate, Meagher & Flom, LLP. Medco's co-lead financial advisors are J.P. Morgan and Lazard, its legal advisor is Sullivan & Cromwell LLP and its regulatory counsel is Dechert LLP.
View Older Stories
-
Express Scripts Announces Final Results of Maximum Tender Offers
-
Express Scripts Announces 2016 Second Quarter Results; Narrows 2016 Full-Year Adjusted Diluted EPS Guidance Range; Raises Mid-Point; Provides 2016 Third Quarter Guidance
-
Express Scripts Announces Pricing of Maximum Tender Offers
-
Express Scripts Announces Early Tender Results and Upsizing of Maximum Tender Offers
-
Express Scripts Announces Early Tender Results and Upsizing of Maximum Tender Offers
-
Fitch Rates Express Scripts' Bonds 'BBB'; Outlook Stable
-
Express Scripts Announces Tender Offers for Outstanding Debt Securities
-
Express Scripts Announces 2016 First Quarter Results; Increases 2016 Guidance Range: Raises Mid-Point; Provides 2016 Second Quarter Guidance
-
Fitch Assigns 'BBB' Rating to Express Scripts' (ESRX) New Bonds
-
Fitch Rates Express Scripts Bonds 'BBB'; Outlook Stable
-
Express Scripts Announces 2015 4th Quarter and Full Year Results; Narrows 2016 Guidance Range: Raises Mid-Point
-
Express Scripts (ESRX) Guides FY16 EPS Above Expectations
-
Express Scripts Holding Company Announces 2016 Financial Guidance and Reaffirms 2015 Financial Guidance
-
Fitch Affirms Express Scripts at 'BBB'; Outlook Stable
-
Express Scripts Announces 3rd Quarter Results; Increases 2015 Guidance Range
-
Express Scripts (ESRX) Names Tim Wentworth as CEO
-
Express Scripts Names Tim Wentworth Chief Executive Officer, Effective May 2016; George Paz to Retire and Remain as Chairman
-
Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range
-
Express Scripts Elects Tim Wentworth to Board of Directors
-
Fitch Rates Express Scripts' New Bank Facility 'BBB'; No Rating Change on $5.5B ASR Program
-
Express Scripts Announces 1st Quarter Results; Announces New Credit Agreement; Narrows 2015 Guidance Range; Maintains Mid-Point
-
Fitch Affirms Express Scripts' Ratings at 'BBB'; Outlook Stable
-
Moody's Moves Outlook on Express Scripts (ESRX) to Positive; Sees Strong Cash Flow Generation
-
VIVUS, Inc. (VVUS) Amends Grid Rebate Program with Express Scripts (ESRX), Medco
-
Cooperman's Omega Advisors Shows New Stakes in AIG (AIG), BofA (BAC), Ford (F), Sprint (S) Among Others Moves
-
Jefferies Reiterates a 'Buy' on Express Scripts (ESRX); Real Boost From MHS Acquisition
-
Notable Mergers and Acquisitions of the Day 04/02: (AVP) (GSK)/(THRX) (DELL) (WWIN)
-
Express Scripts (ESRX) Completes $29.1B Acquisition of Medco
-
S&P Changes: (FOSL) for (MHS) In S&P 500, (BMR) for (FOSL) in S&P MidCap 400; (IPHS) for (BMR) in SmallCap 600
-
Notable Analyst Rating Changes 03/07: (GOOG) (ESRX) (ANR) Upgraded; (P) (KFT) (ZLTQ) Downgraded
-
JMP Cuts Medco (MHS) to Market Perform
-
Cooperman's Omega Advisors Buys Beaten Up Names Like Transocean (RIG) and RIM (RIMM), Sells GM (GM)
-
Express Scripts (ESRX) Announces Benchmark Debt Offering
-
Medco (MHS) Shareholders Give Proposed Express Scripts (ESRX) Merger the 'OK'
-
Express Scripts (ESRX) Unit Prices $4.1B Aggreate Senior Notes Offering
-
TPG-Axon Shows New Stake in Express Scripts (ESRX), Buys More TD Ameritrade (AMTD); Liquidates Sprint (S) and Triquent (TQNT)
-
Express Scripts (ESRX) Reduces Termination Fee in Proposed Merger in Most Instances
-
Glenview Capital Shows New Stakes in BofA (BAC), AIG (AIG) and Crown Castle (CCI); Sells CVS (NYSE: CVS), Pfizer (PFE)
-
Lone Pine Capital Boosts Stake in Apple (AAPL), Opens New Positions in Google (GOOG), Netflix (NFLX), Sells Out of JPMorgan (JPM), MasterCard (MA)
-
Leerink Swann Downgrades Medco Health Solutions (MHS) to Market Perform; Changing Landscape
-
Top 10 News Items 7/18-7/22: Apple Smashes Q3 Estimates; Express Scripts to Buy Medco in $29.1B Deal; Earnings Season Coming In Hot
-
UBS Maintains a 'Buy' on Medco Health Solutions (MHS); FTC Review Prep: Market Share Analysis
-
Unusual 11 Mid-Day Movers 07/21: (SFN) (PRKR) (HEAT) Higher; (TZOO) (NTWK) (EMAN) Lower
-
Morning Movers 07/21: (SFN) (PRKR) (ABAT) (DTLK) Higher; (NTWK) (TZOO) (GNW) (STX) Lower
-
Notable Mergers and Acquisitions of the Day 07/21: (MHS)/(ESRX) (SFN) (NDSN)